Mounjaro is a pharmaceutical drug created by Eli Lilly, approved for managing type 2 diabetes. Its active ingredient, tirzepatide, acts as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, improving blood sugar control and supporting weight management. The medication represents a new class of diabetes treatments that target multiple hormonal pathways to enhance metabolic health.